Open-Label Treatment Extension Study
NCT02896296
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
208
Enrollment
INDUSTRY
Sponsor class
Conditions
Opioid Use Disorder
Opioid-related Disorders
Interventions
DRUG:
RBP-6000
Sponsor
Indivior Inc.